Melahat ÇOBAN, Süleyman DOLU, Yıldız Kılar SÖZER, Bekir EROL, Emre ASİLTÜRK, Hamit ELLİDAĞ, Abdi Metin SARIKAYA

DİYABETES MELLİTUS HASTALARINDA ANJİOGENİK BÜYÜME FAKTÖRLERİ İLE ATEROSKLEROTİK PERİFERİK DAMAR HASTALIKLARININ İLİŞKİSİ

Giriş: Diyabetes mellitus (DM) hastalarında periferik damar hastalıkları sık görülen komplikasyonlardandır. Çalışmamızın amacı tip 2 DM hastalarında anjiopoietin-1(Anj-1), anjiopoietin (Anj-2) ile ateroskleroz, arteriyel sertlik (AS) arasındaki ilişkiyi incelemekti. Gereç ve Yöntem: Bu kesitsel çalışma 65 (%46.4) erkek ve 75 (%53.6) kadın toplam 140 DM hastası ile yapıldı. Karotis arter intima-mediakalınlığı (KA-IMK) ile ateroskleroz varlığı ve brakiyal-ayak bileği nabız dalga hızı (baNDH) aleti ile AS varlığı araştırıldı. Bulgular: Hastalarda sağlıklı bireylere göre KA-IMK, baNDH (p < 0.001), log10 Anj-1 (p = 0.006) ve log10 Anj-2 (p = 0.018) yüksekti. Log10 Anj-1 ile kreatinin (r = -0.241, p = 0.004), spot idrar albumin-kreatinin oranı (SAKO) (r = -0.289, p = 0.001) ve log10 Anj-2 ile kreatinin (r = -0.208, p = 0.014), SAKO (r = -0.269, p = 0.001) arasında ters ilişki gözlendi. Log10 Anj-1 ve log10 Anj-2 ile KA-IMK ve baNDH arasında ilişki gözlenmedi (p > 0.05). Sonuç: DM hastalarında sağlıklı bireylere göre yüksek serum Anj-1 ve Anj-2 düzeyleri gözlendi. Anj-1 ve Anj-2 ile kreatinin ve SAKO arasında ters ilişki gözlendi. Anj-1 ve Anj-2 ile ateroskleroz ve AS arasında ilişki gözlenmedi.

THE RELATIONSHIP BETWEEN ANGIOGENIC GROWTH FACTORS AND ATHEROSCLEROTIC PERIPHERAL VASCULAR DISEASESIN PATIENTS WITH DIABETES MELLITUS

Introduction: Peripheral vascular diseases are common complications in patients with diabetes mellitus (DM). The aim of our study was to investigate the relationship between angiopoietin-1 (Ang-1) and angiopoietin-2 (Ang-2) and atherosclerosis and arterial stiffness (AS) in type 2 DM patients. Material and Methods: This cross-sectional study was conducted with 65 (46.4%) male and 75 (53.6%) female of total 140 DM patients. Presence of atherosclerosis was determined with carotid artery intima-media thickness (CA-IMT) and presence of AS was determined with brachial-ankle pulse wave velocity (baPWV). Results: CA-IMT, baPWV (p 0.05). Conclusion: DM patients had elevated serum Ang-1 and Ang-2 levels compared to healthy subjects. There was an inverse relationship between Ang-1 and Ang-2 and creatinine and UACR. There was no association between Ang-1 and Ang-2 and atherosclerosis and AS.

PDF

___

1. Yonekura H, Yamamoto Y, Sakurai S, Petrova RG, Abedin MJ, Li H et al. Novel splice variants of the receptor for advanced glycation end-products expressed in human vascular endothelial cells and pericytes, and their putative roles in diabetes-induced vascular injury. Biochem J 2003; 370(Pt 3): 1097-109.
2. Fuller JH, Stevens LH, Wang SL. Risk factors for cardiovascular mortality and morbidity: the WHO Mutinational Study of vascular disease in diabetes. Diabetologia 2001; 44(Suppl 2):S54-64.
3. Tsigkos S, Koutsilieris M, Papapetropoulos A. Angiopoietins in angiogenesis and beyond. Expert Opin Investig Drugs 2003; 12(6): 933-41.
4. Reusch P, Barleon B, Weindel K, Martiny-Baron G, Gödde A, Siemeister G, et al. Identification of a soluble form of the angiopoietin receptor TIE-2 released from endothelial cells and present in human blood. Angiogenesis 2001; 4(2): 123-31.
5. Augustin HG, Koh GY, Thurston G, Alitalo K. Control of vascular morphogenesis and homeostasis through the angiopoietin-Tie system. Nat Rev Mol Cell Biol 2009; 10(3): 165-77.
6. Nadar SK, Blann A, Beevers DG, Lip GY. Abnormal angiopoietins 1&2, angiopoietin receptor Tie-2 and vascular endothelial growth factor levels in hypertension: relationship to target organ damage [a sub-study of the AngloScandinavian Cardiac Outcomes Trial (ASCOT)]. J Intern Med 2005; 258(4): 336-43.
7. Post S, Peeters W, Busser E, Lamers D, Sluijter JP, Goumans MJ,et al. Balance between angiopoietin-1 and angiopoietin-2 is in favor of angiopoietin-2 in atherosclerotic plaques with high microvessel density. J Vasc Res 2008; 45(3): 244–50.
8. Lim HS, Lip GY, Blann AD. Angiopoietin-1 and angiopoietin-2 in diabetes mellitus. Relationship to VEGF, glycaemic control,endothelial damage/dysfunction and atherosclerosis. Atherosclerosis 2005; 180(1): 113–8.
9. Chang FC, Chiang WC, Tsai MH,Chou YH, Pan SY, Chang YT, et al.Angiopoietin-2-induced arterial stiffness in CKD. J Am Soc Nephrol 2014; 25(6): 1198-209.
10. Tsai YC, Lee C, Chiu YW, Kuo HT, Lee SC, Hwang SJ, Kuo MC Chen HC. Angiopoietin-2, Angiopoietin-1 and subclinical cardiovascular disease in Chronic Kidney Disease. Sci Rep 2016; 63(6): 39400.
11. Geneva S. Definition, diagnosis and classification of diabetes mellitus and its complications: report of a WHO Consultation. Part 1: Diagnosis and classification of diabetes mellitus. World Health Organisation; 1999.
12. Molitch ME, DeFronzo RA, Franz MJ, Keane WF, Mogensen CE, Parving HH,et al.Nephropathy in diabetes.Diabetes Care 2004; 27(Suppl 1): S79-83.
13. Homma S, Hirose N, Ishida H, Ishii T, Araki G. Carotid plaque and intima-media thickness assessed by B-mode ultrasonography in subjects ranging from young adults to centenarians. Stroke 2001; 32(4): 830-5.
14. Yokoyama H, Shoji T, Kimoto E, Shinohara K, Kanaka S, Koyama H,et al.Pulse wave velocity in lower-limb arteries among diabetic patients with peripheral arterial disease.JAtherosclerThromb 2003; 10(4): 253-8.
15. Lieb W, Zachariah JP, Xanthakis V, Safa R, Chen MH, Sullivan LM,et al. Clinical and genetic correlates of circulating angiopoietin-2 and soluble Tie-2 in the community. Circ Cardiovasc Genet 2010; 3(3): 300-6.
16. Tilton RG, Kawamura T, Chang KC, Ido Y, Bjercke RJ, Stephan CC, et al.Vascular dysfunction induced by elevated glucose levels in rats is mediated by vascular endothelial growth factors. J Clin Invest 1997; 99(9): 2192–202.
17. Okamoto T, Yamagishi S,Inagaki Y, Amano S, Koga K, Abe R, et al. Angiogenesis induced by advanced glycation end products and its prevention by cerivastatin. FASEB J 2002; 16(14): 1928–30.
18. O'Leary DH, Polak JF. Intima-media thickness: a tool for atherosclerosis imaging and event prediction. Am J Cardiol 2002; 90(10C): 18L-21L.
19. Tsuchikura S, Shoji T, Kimoto E, Shinohara K, Hatsuda S, Koyama H,et al. Brachial-ankle pulse wave velocity as an index of central arterial stiffness. J Atheroscler Thromb 2010; 17(6): 658-65.
20. Yamamoto Y, Kato I, Doi T, Yonekura H, Ohashi S, Takeuchi M, et al. Development and prevention of advanced diabetic nephropathy in RAGE-overexpressing mice. J Clin Invest 2001; 108(2): 261–8.
21. Long DA, Norman JT, Fine LG. Restoring the renal microvasculature to treat chronic kidney disease. Nat Rev Nephrol 2012; 8(4): 244-50.
22. Shulman K, Rosen S, Tognazzi K, Manseau E, Brown A. Expression of vascular permeability factor is altered in many glomerular diseases. J Am Soc Nephrol 1996; 7(5): 661–6.
23. David S, John SG, Jefferies HJ, Sigrist MK, Kümpers P, Kielstein JT,et al. Angiopoietin-2 levels predict mortality in CKD patients. Nephrol Dial Transplant 2012; 27(5): 1867–72.
24. Tsai YC, Lee CS, Chiu YW, Kuo HT, Lee SC, Hwang SJ, et al.Angiopoietin-2 as a Prognostic Biomarker of Major Adverse Cardiovascular Events and All-Cause Mortality in Chronic Kidney Disease. PLoS One 2015; 10:e0135181.
25. Marti HH, Risau W. Angiogenesis in ischemic disease. Thromb Haemost 1999; 82(Suppl 1): 44-52.
26. Mayer G. Capillary rarefaction, hypoxia, VEGF and angiogenesis in chronic renal disease. Nephrol Dial Transplant 2011; 26(4): 1132-7.
27. Tuo QH, Zeng H, Stinnett A, Yu H, Aschner JL, Liao DF, et al.Critical role of angiopoietins/Tie-2 in hyperglycemic exacerbation of myocardial infarction and impaired angiogenesis.Am J Physiol Heart Circ Physiol 2008; 294(6): H2547-57.
28. Fiedler U, Reiss Y, Scharpfenecker M, Grunow V, Koidl S, Thurston G, et al.Angiopoietin-2 sensitizes endothelial cells to TNF-alpha and has a crucial role in the induction of inflammation. Nat Med 2006; 12(2): 235-9.
29. Cai J, Kehoe O, Smith GM, Hykin P, Boulton ME. The angiopoietin/Tie-2 system regulates pericyte survival and recruitment in diabetic retinopathy. Invest Ophthalmol Vis Sci 2008; 49(5): 2163-71.
30. Stehouwer CDA, Lambert J, Donker AJM, van Hinsbergh VWM. Endothelial dysfunction and pathogenesis of diabetic angiopathy. Cardiovasc Res 1997; 34(1): 55–68.
31. Nykanen AI, Krebs R, Saaristo A, Turunen P, Alitalo K, Yla-Herttuala S, et al. Angiopoietin-1 protects against the development of cardiac allograft arteriosclerosis. Circulation 2003; 107(9): 1308–14.